Baumgart, D. C. & Carding, S. R. Inflammatory bowel disease: cause and immunobiology. Lancet 369, 1627–1640 (2007).
Maloy, K. J. & Powrie, F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474, 298–306 (2011).
Jairath, V. & Feagan, B. G. Global burden of inflammatory bowel disease. Lancet Gastroenterol. 5, 2–3 (2020).
Cader, M. Z. & Kaser, A. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut 62, 1653–1664 (2013).
Harbour, S. N., Maynard, C. L., Zindl, C. L., Schoeb, T. R. & Weaver, C. T. TH17 cells give rise to TH1 cells that are required for the pathogenesis of colitis. Proc. Natl Acad. Sci. USA 112, 7061–7066 (2015).
Lee, J. Y. et al. Serum amyloid A proteins induce pathogenic TH17 cells and promote inflammatory disease. Cell 180, 79–91 (2020).
Koelink, P. J. et al. Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling. Gut 69, 1053–1063 (2020).
Slevin, S. M. & Egan, L. J. New insights into the mechanisms of action of anti-tumor necrosis factor-α monoclonal antibodies in inflammatory bowel disease. Inflamm. Bowel Dis. 21, 2909–2920 (2015).
Laharie, D. et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 380, 1909–1915 (2012).
Sands, B. E. et al. Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn’s disease: a phase 2a study. Gastroenterology 153, 77–86 (2017).
Sandborn, W. J. et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. Gastroenterology 158, 537–549 (2020).
Khor, B., Gardet, A. & Xavier, R. J. Genetics and pathogenesis of inflammatory bowel disease. Nature 474, 307–317 (2011).
Mirkov, M. U., Verstockt, B. & Cleynen, I. Genetics of inflammatory bowel disease: beyond. Lancet Gastroenterol. 2, 224–234 (2017).
de Lange, K. M. et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat. Genet. 49, 256–261 (2017).
Miceli-Richard, C. et al. CARD15 mutations in Blau syndrome. Nat. Genet. 29, 19–20 (2001).
Lavoie, S. et al. The Crohn’s disease polymorphism, ATG16L1 T300A, alters the gut microbiota and enhances the local TH1/TH17 response. eLife 8, e39982 (2019).
Luo, P., Yang, Z. W., Chen, B. & Zhong, X. M. The multifaceted role of CARD9 in inflammatory bowel disease. J. Cell. Mol. Med. 24, 34–39 (2020).
Lin, Z. W. et al. Genetic association and epistatic interaction of the interleukin-10 signaling pathway in pediatric inflammatory bowel disease. World J. Gastroenterol. 23, 4897–4909 (2017).
Huang, Z. H. et al. Mutations in interleukin-10 receptor and clinical phenotypes in patients with very early onset inflammatory bowel disease: a Chinese VEO-IBD Collaboration Group survey. Inflamm. Bowel Dis. 23, 578–590 (2017).
Franke, A. et al. Genome-wide association study for ulcerative colitis identifies risk loci at 7q22 and 22q13 (IL17REL). Nat. Genet. 42, 292–294 (2010).
Wu, B. J., Jin, M., Zhang, Y., Wei, T. D. & Bai, Z. L. Evolution of the IL17 receptor family in chordates: a new subfamily IL17REL. Immunogenetics 63, 835–845 (2011).
Gaffen, S. L. Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol. 9, 556–567 (2009).
Dubin, P. J. & Kolis, J. K. Interleukin-17A and interleukin-17F: a tale of two cytokines. Immunity 30, 9–11 (2009).
Cua, D. J. & Tato, C. M. Innate IL-17-producing cells: the sentinels of the immune system. Nat. Rev. Immunol. 10, 479–489 (2010).
Datta, S. et al. IL-17 regulates CXCL1 mRNA stability via an AUUUA/tristetraprolin-independent sequence. J. Immunol. 184, 1484–1491 (2010).
Haberman, Y. et al. Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J. Clin. Invest. 124, 3617–3633 (2014).
Zhao, X. M. et al. Mobilization of epithelial mesenchymal transition genes distinguishes active from inactive lesional tissue in patients with ulcerative colitis. Hum. Mol. Genet. 24, 4615–4624 (2015).
Vancamelbeke, M. et al. Genetic and transcriptomic bases of intestinal epithelial barrier dysfunction in inflammatory bowel disease. Inflamm. Bowel Dis. 23, 1718–1729 (2017).
Noack, M., Beringer, A. & Miossec, P. Additive or synergistic interactions between IL-17A or IL-17F and TNF or IL-1β depend on the cell type. Front. Immunol. 10, 1726 (2019).
Kolls, J. K. & Lindén, A. Interleukin-17 family members and inflammation. Immunity 21, 467–476 (2004).
Park, C. H., Lee, A. R., Ahn, S. B., Eun, C. S. & Han, D. S. Role of innate lymphoid cells in chronic colitis during anti-IL-17A therapy. Sci. Rep. 10, 297 (2020).
Zhang, Z., Zheng, M., Bindas, J., Schwarzenberger, P. & Kolls, J. K. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm. Bowel Dis. 12, 382–388 (2006).
Solle, M. et al. Altered cytokine production in mice lacking P2X7 receptors. J. Biol. Chem. 276, 125–132 (2001).
Le Feuvre, R. A., Brough, D., Iwakura, Y., Takeda, K. & Rothwell, N. J. Priming of macrophages with lipopolysaccharide potentiates P2X7-mediated cell death via a caspase-1-dependent mechanism, independently of cytokine production. J. Biol. Chem. 277, 3210–3218 (2002).
Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237–241 (2006).
Mariathasan, S. et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440, 228–232 (2006).
Mempin, R. et al. Release of extracellular ATP by bacteria during growth. BMC Microbiol. 13, 301 (2013).
He, W.-T. et al. Gasdermin D is an executor of pyroptosis and required for interleukin-1β secretion. Cell Res. 25, 1285–1298 (2015).
Shi, J. J. et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526, 660–665 (2015).
Di Virgilio, F., Dal Ben, D., Sarti, A. C., Giuliani, A. L. & Falzoni, S. The P2X7 receptor in infection and inflammation. Immunity 47, 15–31 (2017).
Yang, Y. L. et al. Andrographolide derivative AL-1 ameliorates TNBS-induced colitis in mice: involvement of NF-κB and PPAR-γ signaling pathways. Sci. Rep. 6, 29716 (2016).
Li, B., Alli, R., Vogel, P. & Geiger, T. L. IL-10 modulates DSS-induced colitis through a macrophage–ROS–NO axis. Mucosal Immunol. 7, 869–878 (2014).
Ito, R. et al. Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice. Biochem. Biophys. Res. Commun. 377, 12–16 (2008).
Cominelli, F., Arseneau, K. O., Rodriguez-Palacios, A. & Pizarro, T. T. Uncovering pathogenic mechanisms of inflammatory bowel disease using mouse models of Crohn’s disease-like ileitis: what is the right model? Cell Mol. Gastroenterol. Hepatol. 4, 19–32 (2017).
Zong, Y., Deng, K. H. & Chong, W. P. Regulation of Treg cells by cytokine signaling and co-stimulatory molecules. Front. Immunol. 15, 1387975 (2024).
Wang, J. Y., Zhao, X. Q. & Wan, Y. S. Y. Intricacies of TGF-β signaling in Treg and TH17 cell biology. Cell. Mol. Immunol. 20, 1002–1022 (2023).
Tsuchiya, K. et al. Gasdermin D mediates the maturation and release of IL-1α downstream of inflammasomes. Cell Rep. 34, 108887 (2021).
Bulek, K. et al. Epithelial-derived gasdermin D mediates nonlytic IL-1β release during experimental colitis. J. Clin. Invest. 130, 4218–4234 (2020).
Smillie, C. S. et al. Intra- and inter-cellular rewiring of the human colon during ulcerative colitis. Cell 178, 714–730 (2019).
Maaser, C. et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J. Crohns Colitis 13, 144–164 (2019).
Sturm, A. et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J. Crohns Colitis 13, 273–284 (2019).
Song, X. et al. Growth factor FGF2 cooperates with interleukin-17 to repair intestinal epithelial damage. Immunity 43, 488–501 (2015).
Read more about this post…
Credits: Source
Disclaimer
Serving